C12N 2760/18411
Morbillivirus
Official title: Morbillivirus, e.g. Measles virus, canine distemper
C12N2760/18411 (Morbillivirus) appears on 344 US grants and 427 published applications in this corpus.
Search patents in C12N- Granted patents
- 344
- Published applications
- 427
- Assignees
- 267
- Inventors
- 788
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 3 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 7 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 10 | 0 |
| 1999 | 3 | 0 |
| 2000 | 12 | 0 |
| 2001 | 10 | 5 |
| 2002 | 6 | 10 |
| 2003 | 11 | 11 |
| 2004 | 9 | 8 |
| 2005 | 6 | 13 |
| 2006 | 5 | 10 |
| 2007 | 5 | 10 |
| 2008 | 7 | 16 |
| 2009 | 9 | 6 |
| 2010 | 9 | 17 |
| 2011 | 11 | 16 |
| 2012 | 5 | 9 |
| 2013 | 2 | 13 |
| 2014 | 8 | 16 |
| 2015 | 11 | 18 |
| 2016 | 13 | 16 |
| 2017 | 13 | 25 |
| 2018 | 18 | 31 |
| 2019 | 19 | 19 |
| 2020 | 25 | 26 |
| 2021 | 18 | 20 |
| 2022 | 18 | 14 |
| 2023 | 12 | 29 |
| 2024 | 14 | 29 |
| 2025 | 14 | 21 |
| 2026 | 11 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18434Use of virus or viral component as vaccineIndexing code180
- C12N 2760/18422New viral proteins or individual genes, new structural or functional aspects ofIndexing code137
- C12N 2760/18441Use of virus, viral particle or viral elements as a vectorIndexing code59
- C12N 2760/18421Viruses as suchIndexing code37
- C12N 2760/18451Methods of production or purification of viral materialIndexing code32
- C12N 2760/18432Use of virus as therapeutic agent, other than vaccineIndexing code23
- C12N 2760/18461Methods of inactivation or attenuationIndexing code20
- C12N 2760/18433Use of viral protein as therapeutic agent other than vaccineIndexing code16
Recent patents
- Measles virus vaccine expressing SARS-CoV-2 protein(s)16 Jun 2026US 12,653,881 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Recombinant neuraminidase and uses thereof16 Jun 2026US 12,655,408 B2Icahn School of Medicine at Mount Sinai
- Targeted antigen delivery system and uses thereof26 May 2026US 12,636,378 B2SRI International
- Betacoronavirus mRNA vaccines19 May 2026US 12,629,412 B2ModernaTX, Inc.
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Pseudotyped retroviral vector particle with anti-cd3 display24 Sep 2026US 2026/0286392 A1Miltenyi Biotec GmbH
- In vivo daric17 Sep 2026US 2026/0273058 A1Kelonia Therapeutics, Inc.
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Engineered recombinant retroviruses10 Sep 2026US 2026/0265776 A1Kelonia Therapeutics, Inc.
- Expression construct10 Sep 2026US 2026/0265777 A1Lentitek Ltd
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Process for the production of virus vaccine116US 4,659,569 AKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo · 1987
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Synthetic peptide inhibitors of HIV transmission102US 5,464,933 ADuke University · 1995